TP53

protein-coding

tumor protein p53

Gene summary

This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277). [provided by RefSeq, Dec 2016]

MANE transcript

NM_000546.6

Inheritance

AD

ClinVar variants

P:1313U:894B:851

Top phenotype

Li-Fraumeni syndrome; Choroid plexus papilloma; Ependymoma, intracranial; Osteogenic sarcoma; Breast cancer, familial; Hepatoblastoma; Non-Hodgkin lymphoma; Adrenocortical carcinoma; Colorectal cancer; Bone marrow failure syndrome 5

gnomAD constraint

pLI —, LoF o/e 0.2

Max pathogenic AF

—

Genomic locus

chr17:7,661,779-7,687,546

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~25.8 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

Li-Fraumeni syndromeSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018875

Submitter: Orphanet

Li-Fraumeni syndromeDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018875

Submitter: ClinGen

The TP53 gene encodes p53, a protein with essential roles in genome stability and cellular functions such as cell cycle, metabolism, apoptosis, senescence and differentiation. TP53 was first reported in relation to autosomal dominant Li-Fraumeni syndrome (LFS) in 1991 (Malkin et al., 1991, PMID: 1978757; Li et al., 1998, PMID: 3409256). Numerous variants have been reported in TP53 in relation to the development of Li-Fraumeni syndrome and include missense, small duplications, small deletions, frameshift, and nonsense mutations have been reported in humans. De novo inheritance has been noted in Li-Fraumeni syndrome in 7-20% of cases (Schneider et al., PMID: 20301488). Germline pathogenic variants in TP53 occur in ~70% of individuals with LFS, defined by patterns of personal and family history of certain early onset cancers, mainly premenopausal breast cancer, bone and soft tissue sarcomas, adrenocortical carcinomas and brain tumors (PMID: 33300245). Emerging evidence also suggests the association of ovarian cancer with pathogenic TP53 variants (PMIDs: 26720728, 30733081). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism(s) or inheritance pattern for the different cancers. Therefore, these phenotypes have been lumped into this LFS curation. The molecular mechanisms of TP53 dysfunction for all the associated disease entities listed above are either loss of function or dominant negative; both of which result in reduced (or absent) transcriptional activity and loss of the tumor suppressive function of the p53 protein function. 8 variants (missense, nonsense, frameshift, splicing) from 3 publications in TP53 are included in this curation (PMIDs: 7978053, 8118819, 15381368). Case-control studies also support the disease association (PMIDs: 26720728, 30733081). More evidence is available in the literature, but the maximum score for genetic evidence (12 Points) has been reached. This gene-disease association is also supported by experimental evidence (6 Points; PMIDs: 2046748, 9110404, 12826609, 15607980, 16131611, 29979965, 30224644). Multiple in vitro assays demonstrated the essential role of TP53 as a tumor suppressor. Animal models also showed that heterozygous mice carrying the variants identified from patients with LFS developed multiple tumors. In summary, TP53 is definitively associated with autosomal dominant Li-Fraumeni syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated as definitive for Li-Fraumeni syndrome by the Hereditary Cancer GCEP on 05/13/2020 and as limited for familial ovarian cancer by the Breast/Ovarian Cancer GCEP on 01/10/2018. This re-curation was approved as definitive by the Hereditary Cancer GCEP on 3/22/2024 (SOP Version 10).

Li-Fraumeni syndrome 1DEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0007903

Submitter: Ambry Genetics

colorectal cancerMODERATE

Inheritance Pattern: AD

Disease ID:MONDO:0005575

Submitter: Ambry Genetics

Li-Fraumeni syndrome 1STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0007903

Submitter: Genomics England PanelApp

sarcomaSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0005089

Submitter: Genomics England PanelApp

Li-Fraumeni syndromeDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018875

Submitter: G2P

adrenocortical carcinoma, hereditarySTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0008734

Submitter: Ambry Genetics

bone marrow failure syndrome 5MODERATE

Inheritance Pattern: AD

Disease ID:MONDO:0032573

Submitter: Ambry Genetics

Li-Fraumeni syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0018875

Submitter: Labcorp Genetics (formerly Invitae)

breast cancerDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0007254

Submitter: Ambry Genetics

choroid plexus carcinomaSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0016718

Submitter: Orphanet

Clinical Genomic Database (CGD)

Li-Fraumeni syndrome; Choroid plexus papilloma; Ependymoma, intracranial; Osteogenic sarcoma; Breast cancer, familial; Hepatoblastoma; Non-Hodgkin lymphoma; Adrenocortical carcinoma; Colorectal cancer; Bone marrow failure syndrome 5AD

Manifestation: Allergy/Immunology/Infectious; Hematologic; Neurologic; Oncologic

Intervention: Oncologic

Rationale: For individuals with cancer predisposition, though the optimal course is unclear, surveillance (including breast cancer and colorectal cancer screening starting no later than age 25) and awareness of the increased risk of malignancy could potentially be beneficial in order to allow early diagnosis and treatment; Mastectomy is preferred to lumpectomy in individuals with breast cancer, and may be a prophylactic option; Radiation therapy should be avoided due to the risk of radiation-induced malignancies; For Bone Marrow failure syndrome, individuals have been described as requiring interventions such as blood transfusions and IgG replacement, and awareness may allow prompt management

Comments: Variants may also be involved in susceptibility to a number of types of neoplasms (eg, Basal cell carcinoma, susceptibility to, Glioma, susceptibility to)

Refs: 6016796; 3409256; 1978757; 1679237; 1591732; 1349175; 1565144; 1565143; 8118819; 8718514; 7887414; 9242456; 10612830; 11332399; 11498785; 11600572; 11219776; 11481490; 12085209; 12610779; 12524418; 12619118; 14583457; 12619118; 15381368; 15695383; 15977174; 15741269; 18762572; 19171829; 19556618; 19652052; 20301488; 21056402; 21601526; 21837677; 21946351; 21990040; 22170717; 22551548; 22672556; 22878818; 22939227; 23015295; 23175693; 23355100; 23409989; 23667851; 23894400; 30146126Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to TP53 variants in ClinVar

84 Conditions Cataloged
Li-Fraumeni syndromeTotal: 2481
Hereditary cancer-predisposing syndromeTotal: 2174
Li-Fraumeni syndrome 1Total: 1329
not providedTotal: 643
not specifiedTotal: 325
Ovarian neoplasmTotal: 231
Adrenocortical carcinoma, hereditaryTotal: 193
TP53-related disorderTotal: 131

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_000546.6. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
3
clinvar
9
clinvar
10
clinvar
451
clinvar
35
clinvar
508
missense
116
clinvar
349
clinvar
721
clinvar
328
clinvar
36
clinvar
1550
nonsense
89
clinvar
19
clinvar
5
clinvar
113
start loss
2
clinvar
2
frameshift
504
clinvar
80
clinvar
119
clinvar
1
clinvar
704
splice donor/acceptor (+/-2bp)
38
clinvar
104
clinvar
39
clinvar
181
Total752561894780713058

Highest pathogenic variant AF is 0.000014869078

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 73 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_000546.6RefSeqNP_000537.310MANE Select
ENST00000269305.9EnsemblENSP00000269305.410MANE Select
NM_001126112.3RefSeqNP_001119584.110Standard
NM_001126113.3RefSeqNP_001119585.19Standard

Model Organisms & Knockout Phenotypes

Observed phenotypic effects in mouse and zebrafish models

Gene / ModelOrganismObserved Phenotype
tp53Danio rerio

Structure: nucleate erythrocyte

Quality: immature

abnormal

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Fluoropyrimidine Pathway, Pharmacodynamics
  • PI3K-Akt signaling pathway - Homo sapiens (human)
  • Non-small cell lung cancer - Homo sapiens (human)
  • Chronic myeloid leukemia - Homo sapiens (human)
  • Gastric cancer - Homo sapiens (human)

Biological Process

  • negative regulation of transcription by RNA polymerase II
  • DNA strand renaturation
  • base-excision repair
  • nucleotide-excision repair
  • regulation of transcription, DNA-templated

Molecular Function

  • RNA polymerase II proximal promoter sequence-specific DNA binding
  • RNA polymerase II distal enhancer sequence-specific DNA binding
  • DNA-binding transcription factor activity, RNA polymerase II-specific
  • core promoter sequence-specific DNA binding
  • RNA polymerase II transcription factor binding

Cellular Component

  • nuclear chromatin
  • nucleus
  • nucleoplasm
  • transcription factor complex
  • transcription factor TFIID complex

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000269305
Coding exons
10
Length
25760
Individuals with no LoFs
125740
Homozygous LoFs
0
Heterozygous LoFs
8
Defined
125748
p
0.0000318
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense0.9831922340.8190.00001532531
Missense (PolyPhen)7295.3190.755361053
Synonymous-0.5449689.51.070.00000581780
Loss of Function3.26419.50.2050.00000111220

Population LoF Frequency

PopulationCAFp-valueStatus
African0.0000620.000062rare
Latino/Admixed American00.0absent
Ashkenazi Jewish00.0absent
East Asian0.0000540.000054rare
Finnish00.0absent
European (Non-Finnish)0.0000440.000044rare
South Asian0.0000330.000033rare
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA- Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1- mediated transcriptional activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, ECO:0000269|PubMed:9840937}.;
Disease
DISEASE: Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.; DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: An autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor of neuroectodermal origin that generally occurs in childhood, but has also been reported in adults. Although generally found within the ventricular system, choroid plexus papillomas can arise ectopically in the brain parenchyma or disseminate throughout the neuraxis. Patients present with signs and symptoms of increased intracranial pressure including headache, hydrocephalus, papilledema, nausea, vomiting, cranial nerve deficits, gait impairment, and seizures. {ECO:0000269|PubMed:12085209}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant neoplasm of the adrenal cortex and a rare childhood tumor. It occurs with increased frequency in patients with Beckwith- Wiedemann syndrome and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant skin neoplasm that typically appears on hair-bearing skin, most commonly on sun-exposed areas. It is slow growing and rarely metastasizes, but has potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters in diameter. {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;

Recessive Scores

pRec
1.00

Intolerance Scores

LoFtool
0.000965
RVIS EVS
-0.25
RVIS percentile EVS
35.99

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
S
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
1.00

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.